Used in the management of type 2 diabetes mellitus as an oral antihyperglycemic agent. It functions by inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme, which increases the levels of active incretin hormones such as GLP-1 and GIP. This enhances glucose-dependent insulin release from pancreatic beta cells and reduces glucagon secretion, leading to lower fasting and postprandial blood glucose levels. Typically prescribed as monotherapy or in combination with other antidiabetic agents like metformin, sulfonylureas, or insulin. Its use improves glycemic control without significant risk of hypoglycemia or weight gain, making it suitable for long-term diabetes management.